The Antibody Drug Conjugates Market Report by ResearchAndMarkets.com shows that the global market size for antibody drug conjugates reached US$7.8 billion in 2023 and is projected to reach US$43.7 billion by 2032 with a growth rate of 21.1% during 2023-2032. The increase in cancer prevalence due to sedentary lifestyles, smoking, and drinking habits is a key factor driving market growth. The demand for cost-effective and successful cancer treatments is also contributing to market expansion.
Leading players in the industry are investing in research and development to optimize chemical triggers for ADCs, develop novel linkers, and improve linker-antibody attachments to create stable and homogenous ADCs. They are also focusing on enhancing absorption, distribution, metabolism, and excretion processes to improve treatment outcomes. Factors such as improving healthcare infrastructure, increasing awareness about cancer therapies, and the introduction of cleavable linker technology are expected to further boost market growth.
The report categorizes the market based on components, targets, applications, and end-users. Components include monoclonal antibodies, linkers, cytotoxic agents, and others. Target categories consist of antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small molecule drug conjugates, and antibody-enzyme conjugates. Applications cover lymphoma, ovarian cancer, lung cancer, breast cancer, brain tumor, and others. End-users include hospitals, specialized cancer centers, academic research institutes, biotechnology companies, and others.
The market is segmented by region into North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. The competitive landscape of the industry features profiles of key players such as ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca PLC, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline PLC, ImmunoGen Inc., Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc., and Takeda Pharmaceutical Company Ltd.
The report provides insights into key trends in each sub-segment of the global antibody drug conjugates market with forecasts at the global, regional, and country levels from 2024-2032. It offers a comprehensive analysis of the industry’s competitive landscape and key player profiles, along with detailed information on market value, growth rate, and forecast period. For more information about this report, visit the ResearchAndMarkets.com website.
ResearchAndMarkets.com is a leading source for international market research reports and data, offering the latest information on global and regional markets, key industries, top companies, new products, and emerging trends.